Deep Track Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Deep Track Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-105,085	Closed	-$2.24M	–	56
2025 Q3	$2.24M	Buy	+105,085	New	+$2.49M	0.06%	52
2022 Q3	–	Sell	-1,733,130	Closed	-$24.4M	–	66
2022 Q2	$24.4M	Buy	+1,733,130	New	+$32.3M	1.61%	23

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Deep Track Capital's ACAD Position: Q4 2025 in Review

Deep Track Capital sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 105,085 shares — an estimated $2.24M sold.

Deep Track Capital first reported a position in ACAD in Q2 2022 and held it in 2 quarters. The position peaked at $24.4M in Q2 2022. 335 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

Deep Track Capital reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Deep Track Capital sold 105,085 Acadia Pharmaceuticals shares in Q4 2025, an estimated $2.24M.
Deep Track Capital first reported a position in Acadia Pharmaceuticals in Q2 2022 and held it in 2 quarters.
Deep Track Capital's Acadia Pharmaceuticals position peaked at $24.4M in Q2 2022.
335 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Deep Track Capital's 13F filing for Q4 2025, filed 13 Feb 2026.